Background: Non-concordance with medication remains a major public health problem that imposes a considerable financial burden on the health care system, and there is still a need for studies on ...

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and growing patient population Study design intended ...

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price target of $10.00. Joseph Pantginis has given his Buy ...

MEMPHIS, Tenn. - Not a whole lot to update here...its practically perfect out. We have another beautiful day ahead with sunshine, dry skies and temperatures that are a little above average in the ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique ...

"Just like our Chairman Mao said, 'make each step steadily, and gradually we will make ourselves strong'." ...